Test Page
Symposium
Symposium

Test Page

For Testing Purposes

Not a member of My prIME? Join now for instant access.

To apply for a travel grant, click on the Register Now button.

Also, restricted activity, blah blah blah

Meeting Overview

Get the latest updates on current and emerging asparaginase therapies in pediatric ALL at this interactive satellite symposium. A variety of topics will be discussed, including mechanism of action and pharmacokinetics, monitoring and management of asparaginase toxicities, and communication approaches specific to pediatric patients and their families. Attendees will have the opportunity to interact with expert faculty throughout the symposium.

This meeting will be held in conjunction with the Association of Pediatric Hematology/Oncology Nurses 42nd Annual Conference & Exhibit. Event staff will be glad to assist you with any special needs (physical, dietary, etc).

Andreas du Bois, MD, PhD
Chair

Jonathan Ledermann, BSc, MD, FRCP
Chair

Ignace Vergote, MD, PhD
Chair

Date and Location

Saturday, September 15, 2018
12.45 PM – 2.00 PM

Chatham Ballroom ABC
Savannah International Trade & Convention Center
1 International Drive
Savannah, Georgia 31421

Date/Time

Date/Time

25 – 26 January 2019

Location

Location

Barcelona, Spain

IME

IME

Saturday, September 15, 2018

12.45 PM Program overview
Belinda Mandrell, PhD, RN
12.50 PM Hematology Guru: What do you know about asparaginase toxicities?
Belinda Mandrell, PhD, RN
12.55 PM Asparaginase review
Katie Gettinger, MSN, RN, CPNP
1.12 PM Interactive audience Q&A
1.17 PM Identification and management of asparaginase toxicities
Anna Lefebvre, MSN, RN, CPNP, CPON
Joan Ronan, MSN, RN, CPNP, CPON
1.40 PM Interactive audience Q&A
1.45 PM Assessing what you have learned from this activity: Have you increased your “guru” status?
Belinda Mandrell, PhD, RN
1.55 PM prIME Points™
Belinda Mandrell, PhD, RN
2.00 PM Adjourn

    Chair

  • Belinda Mandrell, PhD, RNSt Jude Children’s Research Hospital
    Memphis, Tennessee, United States
  • Faculty

  • Katie Gettinger, MSN, RN, CPNP-PCSt Louis Children’s Hospital
    St Louis, Missouri, United States
  • Anna Lefebvre, MSN, RN, CPNP, CPONDana Farber/ Boston Children’s Cancer and Blood Disorders Center
    Boston, Massachusetts, United States
  • Joan Ronan, MSN, RN, CPNP, CPONDana Farber/Boston Children’s Cancer and Blood Disorders Center
    Boston, Massachusetts, United States

*Additional faculty to be confirmed

This educational activity is designed to meet the needs of registered nurses and advanced practice registered nurses who provide care for pediatric patients with acute lymphoblastic leukemia (ALL).

After successful completion of this educational activity, participants should be able to:

  • Discuss current and emerging asparaginase therapies for pediatric patients, including mechanism of action, structure, bacterial source, and pharmacokinetics
  • Implement clinical nursing approaches for the monitoring and management of asparaginase toxicities for pediatric patients with ALL
  • Describe best practices in patient/family education and communication to improve outcomes for pediatric patients with ALL

Registration Fees

Physician

  • Early: €395
  • Regular: €495
  • Late: €595

Nurse

  • Early: €225
  • Regular: €300
  • Late: €375

Fellow/Resident/Student*

  • Early: €225
  • Regular: €300
  • Late: €375

Industry

  • Early: €525
  • Regular: €625
  • Late: €725

Registration fees include VAT.
*Support documentation of eligibility may be required.

Your registration fee will include:

  • Access to all sessions and exhibition
  • Lunch and coffee breaks
  • Conference documentation

Registration Deadlines
Early registration rate: 22 November 2018 (23.59 CET)
Regular registration rate: 20 December 2018 (23.59 CET)

To Register
You may register online through 23 January 2019 via the “Register Now” button at the top of this page. Registration confirmations will be issued upon successful completion of registration, and reminders will be issued before the meeting. To preregister, registration and payment must be received no later than either 22 November 2018 (early registration rate) or 20 December 2018 (regular registration rate). Please register onsite after 23 January 2019.

Group Registrations
Group registrations will be accepted. For more information, please click “Contact prIME Oncology” at the bottom of this page.

Terms of Payment
All payments must be made in Euros. Payments can be made by credit card.

Registration will only be valid upon prIME Oncology’s receipt of full payment. Outstanding payment must be settled onsite by credit card.

Cancellation
To receive a refund of registration fees, written notice of cancellation must be received. To submit notice of cancellation, please click “Contact prIME Oncology” at the bottom of this page.

The following deadlines and cancellation fee schedule will apply:

  • Before 22 November 2018: €50 administrative charge
  • 22 November 2018 — 19 December 2018: 60% cancellation fee applies on registration fee(s)
  • From 20 December 2018: 100% cancellation fee applies on registration fee(s)
  • Name changes from 20 December 2018: €15 fee is charged per change

Any registration fees remitted will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after 20 December 2018.

prIME Oncology does not accept responsibility for reimbursement of travel, accommodation, or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

[SPEAKER NAME] has disclosed ______. S/He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

The employees of prIME Oncology have disclosed:

  • Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Angela Zimmermann, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Susan McKinney (editorial content reviewer) – no relevant financial relationships

The PIM planners and managers have nothing to disclose.

There is no fee for this educational activity.

This educational activity is supported by a grant from Shire.

INDEPENDENT MEDICAL EDUCATION (IME)

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine (PIM) and prIME Oncology assess the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by PIM and prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. PIM and prIME Oncology are committed to providing their learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

Provider

This activity is jointly provided by prIME Oncology and Postgraduate Institute for Medicine.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.